Are you Dr. Martin?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 45 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
607 Garfield St
Tupelo, MS 38801Phone+1 662-840-5200Fax+1 662-840-8216- Is this information wrong?
Summary
- Dr. Sherry Martin, MD is an endocrinologist in Tupelo, Mississippi. She is currently licensed to practice medicine in Mississippi.
Education & Training
Ochsner Clinic FoundationFellowship, Endocrinology, Diabetes, and Metabolism, 1990 - 1992
University of North Carolina HospitalsFellowship, Clinical Pharmacology, 1985 - 1986- University of North Carolina HospitalsResidency, Internal Medicine, 1982 - 1985
University of Mississippi School of MedicineClass of 1982
Certifications & Licensure
MS State Medical License 1983 - 2020
Publications & Presentations
PubMed
- 9 citationsLilly Calls into Question the Validity of Published Insulin Concentration Results.Ann Connery, Sherry Martin> ;Journal of Diabetes Science and Technology. 2018 Mar 7
- 32 citationsDulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 Trials.Paolo Pozzilli, Richard David Leslie, Anne L. Peters, Raffaella Buzzetti, Sudha S. Shankar, Zvonko Milicevic, Imre Pavo, Jeremie Lebrec, Sherry Martin, Nanette C. Schloot> ;Diabetes, Obesity & Metabolism. 2018 Jun 1
- Network meta-analysis accurately predicted the outcome of a subsequent randomised trial comparing once weekly dulaglutide 1.5 mg and once daily liraglutide 1.8 mg.Fahrbach, J. L.,Fu, H.,Shurzinske, L.,Skrivanek, Z.,Martin, S.> ;Int. J. Clin. Pract.. 2016 Feb 27
- Join now to see all
Press Mentions
Dulaglutide Receives FDA Approval for Reducing MACE in Type 2 DiabeticsFebruary 24th, 2020
Empagliflozin Better for Patients at High Cardiovascular RiskNovember 21st, 2019
Powder-Delivery Device Approved for First and Only Nasally Administered GlucagonJuly 30th, 2019- Join now to see all
